vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $131.8M, roughly 1.3× Loar Holdings Inc.). Loar Holdings Inc. runs the higher net margin — 9.5% vs 1.6%, a 7.9% gap on every dollar of revenue. On growth, Loar Holdings Inc. posted the faster year-over-year revenue change (19.3% vs 5.0%). Over the past eight quarters, Loar Holdings Inc.'s revenue compounded faster (19.8% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LOAR vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $177.4M |
| Net Profit | $12.5M | $2.9M |
| Gross Margin | 52.1% | — |
| Operating Margin | 18.0% | 3.9% |
| Net Margin | 9.5% | 1.6% |
| Revenue YoY | 19.3% | 5.0% |
| Net Profit YoY | 239.5% | — |
| EPS (diluted) | $0.13 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $131.8M | $196.9M | ||
| Q3 25 | $126.8M | $179.5M | ||
| Q2 25 | $123.1M | $181.1M | ||
| Q1 25 | $114.7M | $168.9M | ||
| Q4 24 | $110.4M | $187.3M | ||
| Q3 24 | $103.5M | $168.6M | ||
| Q2 24 | $97.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.5M | — | ||
| Q3 25 | $27.6M | $5.4M | ||
| Q2 25 | $16.7M | $-4.8M | ||
| Q1 25 | $15.3M | $4.8M | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $8.7M | $-143.5M | ||
| Q2 24 | $7.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 52.1% | 79.5% | ||
| Q3 25 | 52.7% | 80.9% | ||
| Q2 25 | 53.8% | 77.4% | ||
| Q1 25 | 52.1% | 79.7% | ||
| Q4 24 | 48.9% | 78.7% | ||
| Q3 24 | 51.1% | 76.9% | ||
| Q2 24 | 49.0% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 18.0% | 1.2% | ||
| Q3 25 | 22.9% | 3.5% | ||
| Q2 25 | 22.2% | 4.7% | ||
| Q1 25 | 22.8% | 1.2% | ||
| Q4 24 | 19.2% | 13.2% | ||
| Q3 24 | 22.1% | -82.8% | ||
| Q2 24 | 22.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 9.5% | — | ||
| Q3 25 | 21.8% | 3.0% | ||
| Q2 25 | 13.6% | -2.7% | ||
| Q1 25 | 13.4% | 2.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 8.4% | -85.1% | ||
| Q2 24 | 7.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.13 | $0.05 | ||
| Q3 25 | $0.29 | $0.12 | ||
| Q2 25 | $0.17 | $-0.11 | ||
| Q1 25 | $0.16 | $0.10 | ||
| Q4 24 | $-11023.48 | $0.38 | ||
| Q3 24 | $0.09 | $-3.11 | ||
| Q2 24 | $0.09 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $144.3M |
| Total DebtLower is stronger | $715.7M | — |
| Stockholders' EquityBook value | $1.2B | $653.9M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $84.8M | $238.4M | ||
| Q3 25 | $99.0M | $246.3M | ||
| Q2 25 | $103.3M | $445.9M | ||
| Q1 25 | $80.5M | $493.6M | ||
| Q4 24 | $54.1M | $484.6M | ||
| Q3 24 | $55.2M | $453.8M | ||
| Q2 24 | $73.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $715.7M | $372.2M | ||
| Q3 25 | $279.4M | $376.7M | ||
| Q2 25 | $277.7M | $580.5M | ||
| Q1 25 | $277.5M | $583.4M | ||
| Q4 24 | $277.3M | $585.3M | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.2B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.1B | $778.3M | ||
| Q3 24 | $769.8M | $749.6M | ||
| Q2 24 | $758.4M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.5B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | 0.54× | ||
| Q3 25 | 0.24× | 0.52× | ||
| Q2 25 | 0.25× | 0.77× | ||
| Q1 25 | 0.25× | 0.73× | ||
| Q4 24 | 0.25× | 0.75× | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 2.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $43.7M | ||
| Q3 25 | $29.7M | $60.8M | ||
| Q2 25 | $23.8M | $12.0M | ||
| Q1 25 | $28.4M | $35.5M | ||
| Q4 24 | $20.7M | $33.1M | ||
| Q3 24 | $16.3M | $53.9M | ||
| Q2 24 | $7.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | 11.20× | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | 7.37× | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
